/STMM

STMM Stock - Stemcell Holdings, Inc.

Q: What is the analyst price target for STMM?

Analyst price target information is not currently available for STMM.

Q: What is STMM's market cap?

Market capitalization information is not currently available for STMM.

Healthcare|Biotechnology|OTC

$0.06+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.07

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for STMM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2016

FY2017

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.00

52W High$0.06

52W Low$0.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2017	FY2016
Revenue	$6.18M	$3.34M
Gross Profit	$4.99M	$2.97M
Gross Margin	80.8%	88.9%
Operating Income	$3.60M	$2.65M
Net Income	$2.41M	$1.40M
Net Margin	39.0%	42.0%
EPS	$0.09	$0.05

Company Overview

Stemcell Holdings, Inc., through its subsidiary, Stemcell Co., Ltd., engages in the regenerative medicine-related business. It provides technical assistance services to the culturing, storing, and delivery of stem cells; and administrative and consulting services to clinics. The company offers two different options for stem cell regenerative therapy, including autologous adipose derived mesenchymal stem cells and natural killer cells. It also provides coordination services to facilitate its stem cell culturing business, which comprise the introduction of patients to clinics, arranging patients' schedules, and translating between patients and clinics due to language barriers. In addition, Stemcell Holdings, Inc. offers Internet marketing services through search engine optimization for clinics; and property and equipment rental services. The company was formerly known as Perfect Acquisition, Inc., and changed its name to Stemcell Holdings, Inc. in January 2016. Stemcell Holdings, Inc. was founded in 2015 and is based in Tokyo, Japan. as of May 2, 2016, Stemcell Holdings, Inc. operates as a subsidiary of Primavera Singa Pte Ltd.

Visit Website